vs
Alector, Inc.（ALEC）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是Alector, Inc.的72.4倍（$451.8M vs $6.2M）。HALOZYME THERAPEUTICS, INC.净利率更高（-31.3% vs -597.5%，领先566.2%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs -88.5%）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
ALEC vs HALO — 直观对比
营收规模更大
HALO
是对方的72.4倍
$6.2M
营收增速更快
HALO
高出140.1%
-88.5%
净利率更高
HALO
高出566.2%
-597.5%
两年增速更快
HALO
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $451.8M |
| 净利润 | $-37.3M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -634.4% | -20.6% |
| 净利率 | -597.5% | -31.3% |
| 营收同比 | -88.5% | 51.6% |
| 净利润同比 | -1696.9% | -203.3% |
| 每股收益（稀释后） | $-0.34 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECHALO
| Q4 25 | $6.2M | $451.8M | ||
| Q3 25 | $3.3M | $354.3M | ||
| Q2 25 | $7.9M | $325.7M | ||
| Q1 25 | $3.7M | $264.9M | ||
| Q4 24 | $54.2M | $298.0M | ||
| Q3 24 | $15.3M | $290.1M | ||
| Q2 24 | $15.1M | $231.4M | ||
| Q1 24 | $15.9M | $195.9M |
净利润ALECHALO
| Q4 25 | $-37.3M | $-141.6M | ||
| Q3 25 | $-34.7M | $175.2M | ||
| Q2 25 | $-30.5M | $165.2M | ||
| Q1 25 | $-40.5M | $118.1M | ||
| Q4 24 | $-2.1M | $137.0M | ||
| Q3 24 | $-42.2M | $137.0M | ||
| Q2 24 | $-38.7M | $93.2M | ||
| Q1 24 | $-36.1M | $76.8M |
毛利率ALECHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率ALECHALO
| Q4 25 | -634.4% | -20.6% | ||
| Q3 25 | -1153.6% | 61.5% | ||
| Q2 25 | -433.6% | 62.2% | ||
| Q1 25 | -1216.5% | 53.4% | ||
| Q4 24 | -13.4% | 58.9% | ||
| Q3 24 | -315.7% | 56.3% | ||
| Q2 24 | -302.4% | 50.7% | ||
| Q1 24 | -275.0% | 48.8% |
净利率ALECHALO
| Q4 25 | -597.5% | -31.3% | ||
| Q3 25 | -1063.4% | 49.5% | ||
| Q2 25 | -387.7% | 50.7% | ||
| Q1 25 | -1101.6% | 44.6% | ||
| Q4 24 | -3.8% | 46.0% | ||
| Q3 24 | -275.2% | 47.2% | ||
| Q2 24 | -256.4% | 40.3% | ||
| Q1 24 | -227.0% | 39.2% |
每股收益（稀释后）ALECHALO
| Q4 25 | $-0.34 | $-1.13 | ||
| Q3 25 | $-0.34 | $1.43 | ||
| Q2 25 | $-0.30 | $1.33 | ||
| Q1 25 | $-0.41 | $0.93 | ||
| Q4 24 | $-0.02 | $1.06 | ||
| Q3 24 | $-0.43 | $1.05 | ||
| Q2 24 | $-0.40 | $0.72 | ||
| Q1 24 | $-0.38 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $133.8M |
| 总债务越低越好 | $10.0M | $2.1B |
| 股东权益账面价值 | $30.6M | $48.8M |
| 总资产 | $293.2M | $2.5B |
| 负债/权益比越低杠杆越低 | 0.33× | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资ALECHALO
| Q4 25 | $256.0M | $133.8M | ||
| Q3 25 | $291.1M | $419.7M | ||
| Q2 25 | $307.3M | $61.9M | ||
| Q1 25 | $354.6M | $176.3M | ||
| Q4 24 | $413.4M | $115.8M | ||
| Q3 24 | $457.2M | $154.3M | ||
| Q2 24 | $503.3M | $187.9M | ||
| Q1 24 | $562.1M | $164.6M |
总债务ALECHALO
| Q4 25 | $10.0M | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $10.0M | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益ALECHALO
| Q4 25 | $30.6M | $48.8M | ||
| Q3 25 | $57.7M | $503.9M | ||
| Q2 25 | $71.2M | $332.7M | ||
| Q1 25 | $94.6M | $482.3M | ||
| Q4 24 | $126.8M | $363.8M | ||
| Q3 24 | $118.9M | $452.7M | ||
| Q2 24 | $150.6M | $289.4M | ||
| Q1 24 | $178.9M | $177.8M |
总资产ALECHALO
| Q4 25 | $293.2M | $2.5B | ||
| Q3 25 | $335.3M | $2.2B | ||
| Q2 25 | $356.4M | $2.1B | ||
| Q1 25 | $408.3M | $2.2B | ||
| Q4 24 | $468.3M | $2.1B | ||
| Q3 24 | $516.0M | $2.1B | ||
| Q2 24 | $570.7M | $2.0B | ||
| Q1 24 | $635.5M | $1.8B |
负债/权益比ALECHALO
| Q4 25 | 0.33× | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | 0.08× | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | — | $217.6M |
| 自由现金流率自由现金流/营收 | — | 48.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $644.6M |
8季度趋势，按日历期对齐
经营现金流ALECHALO
| Q4 25 | $-41.7M | $219.0M | ||
| Q3 25 | $-32.5M | $178.6M | ||
| Q2 25 | $-49.0M | $99.7M | ||
| Q1 25 | $-60.8M | $154.2M | ||
| Q4 24 | $-55.0M | $178.5M | ||
| Q3 24 | $-50.7M | $115.4M | ||
| Q2 24 | $-62.8M | $55.8M | ||
| Q1 24 | $-61.3M | $129.4M |
自由现金流ALECHALO
| Q4 25 | — | $217.6M | ||
| Q3 25 | $-32.5M | $175.6M | ||
| Q2 25 | $-49.1M | $98.1M | ||
| Q1 25 | $-60.8M | $153.3M | ||
| Q4 24 | $-55.2M | $175.4M | ||
| Q3 24 | $-50.9M | $113.9M | ||
| Q2 24 | $-63.1M | $53.2M | ||
| Q1 24 | $-61.9M | $125.9M |
自由现金流率ALECHALO
| Q4 25 | — | 48.2% | ||
| Q3 25 | -997.6% | 49.6% | ||
| Q2 25 | -623.0% | 30.1% | ||
| Q1 25 | -1655.0% | 57.9% | ||
| Q4 24 | -101.8% | 58.9% | ||
| Q3 24 | -332.1% | 39.3% | ||
| Q2 24 | -418.6% | 23.0% | ||
| Q1 24 | -389.3% | 64.3% |
资本支出强度ALECHALO
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.3% | 0.9% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.5% | 0.4% | ||
| Q4 24 | 0.3% | 1.0% | ||
| Q3 24 | 1.4% | 0.5% | ||
| Q2 24 | 2.2% | 1.1% | ||
| Q1 24 | 3.4% | 1.8% |
现金转化率ALECHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEC
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
